SUMATRIPTAN SUCCINATE tablet

País: Estados Unidos

Idioma: inglés

Fuente: NLM (National Library of Medicine)

Ingredientes activos:

SUMATRIPTAN SUCCINATE (UNII: J8BDZ68989) (SUMATRIPTAN - UNII:8R78F6L9VO)

Disponible desde:

NuCare Pharmaceuticals,Inc.

Vía de administración:

ORAL

tipo de receta:

PRESCRIPTION DRUG

indicaciones terapéuticas:

Sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.   Limitations of Use: • Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan, reconsider the diagnosis of migraine before sumatriptan tablets are administered to treat any subsequent attacks. • Sumatriptan tablets are not indicated for the prevention of migraine attacks. • Safety and effectiveness of sumatriptan tablets have not been established for cluster headache. Sumatriptan tablets are contraindicated in patients with: • Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina [see Warnings and Precautions ( 5.1 )] • Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (

Resumen del producto:

Sumatriptan tablets USP, 100 mg are white, capsule shaped, biconvex film-coated tablets debossed with RDY on one side and 293 on the other side. NDC 68071-2283-9 Unit of use blister pack of 9 (1 x 9) Store at 20 ° to 25°C (68 ° – 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

Estado de Autorización:

Abbreviated New Drug Application

Ficha técnica

SUMATRIPTAN SUCCINATE- SUMATRIPTAN SUCCINATE TABLET
NUCARE PHARMACEUTICALS,INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
SUMATRIPTAN TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
SUMATRIPTAN TABLETS.
SUMATRIPTAN TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1992
INDICATIONS AND USAGE
Sumatriptan is a serotonin (5-HT
) receptor agonist (triptan) indicated for acute treatment of migraine
with or without aura in adults. ( 1)
Limitations of Use:
Use only if a clear diagnosis of migraine headache has been
established. ( 1)
Not indicated for the prophylactic therapy of migraine attacks. ( 1)
Not indicated for the treatment of cluster headache. ( 1)
DOSAGE AND ADMINISTRATION
Single dose of 25 mg, 50 mg, or 100 mg tablet.( 2.1)
A second dose should only be considered if some response to the first
dose was observed. Separate
doses by at least 2 hours. ( 2.1)
Maximum dose in a 24-hour period: 200 mg. ( 2.1)
Maximum single dose should not exceed 50 mg in patients with mild to
moderate hepatic impairment. (
2.2)
DOSAGE FORMS AND STRENGTHS
Tablets: 25 mg, 50 mg, and 100 mg ( 3)
CONTRAINDICATIONS
History of coronary artery disease or coronary artery vasospasm ( 4)
Wolff-Parkinson-White syndrome or other cardiac accessory conduction
pathway disorders ( 4)
History of stroke, transient ischemic attack, or hemiplegic or basilar
migraine ( 4)
Peripheral vascular disease ( 4)
Ischemic bowel disease ( 4)
Uncontrolled hypertension ( 4)
Recent (within 24 hours) use of another 5-HT
agonist (e.g., another triptan) or of an ergotamine-
containing medication. ( 4)
Concurrent or recent (past 2 weeks) use of monoamine oxidase-A
inhibitor. ( 4)
Hypersensitivity to sumatriptan (angioedema and anaphylaxis seen). (
4)
Severe hepatic impairment. ( 4)
WARNINGS AND PRECAUTIONS
Myocardial ischemia/infarction and Prinzmetal’s angina: Perform
cardiac evaluation in patients with
multiple cardiovascular risk factors. ( 5.1)
Arrhythmias: Discontinue sumatrip